Sanders Corazon (Corsee) D. sold $259K of LEGN

Sanders Corazon (Corsee) D. sold 27,370 shares of Legend Biotech Corp (LEGN) at $9.46 ($0.26M total) on 2026-09-29.

Original reporting
SEC EDGAR · Sanders Corazon (Corsee) D.
Published Oct 1, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LEGN
Bearish
medium confidence
Mentioned
$LEGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNBearishLow
01

Why it matters

The director's sale may be interpreted as a lack of confidence, but the amount is modest relative to the company's market cap.

02

Market read

Provides a fresh, albeit small, insider sell signal for Legend Biotech.

03

What to watch

Potential upcoming clinical data releases could offset the sell pressure.

Relevance 4/10Novelty 3/10Timing: same-day filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$LEGNBearishMedium confidence
Context

Director Sanders Corazon sold 27,370 shares of Legend Biotech for $258,920 on Sep 29, 2026.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A director sold a sizable block at $9.46 per share, indicating potential concerns; however the amount is relatively small for the market.

Market effects

Minimal impact on the biotech sector; typical insider sales are routine.

No significant regional effect.

Limited to Legend Biotech investors.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Legend Biotech Corp

    Biotech firm listed on Nasdaq under ticker LEG N.

  • Sanders Corazon D.

    Director of Legend Biotech who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.